07Nov/13

UC researchers receive FDA grant to study generic tacrolimus in high-risk … – News-Medical.net

Immunosuppressive Drugs

UC researchers receive FDA grant to study generic tacrolimus in high-risk …
News-Medical.net
Tacrolimus is a “cornerstone drug” in post-transplant immunosuppression, used after transplant to reduce the activity of the patient’s immune system and lower the risk of rejection. Generic versions were introduced in 2009. Currently Alloway estimates …
$2.3M grant to University of Cincinnati could help organ transplant patientsCincinnati Business Courier

all 2 news articles »
29Oct/13

STENTYS Sirolimus-Eluting Stent Demonstrates Faster Arterial Healing Than … – PharmiWeb.com (press release)

Immunosuppressive Drugs

STENTYS Sirolimus-Eluting Stent Demonstrates Faster Arterial Healing Than …
PharmiWeb.com (press release)
STENTYS (FR0010949404 – STNT) a medical technology company commercializing in Europe the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI) announced today results from the 4-month arm of the APPOSITION IV …

and more »
29Oct/13

STENTYS Sirolimus-Eluting Stent Demonstrates Faster Arterial Healing Than … – MarketWatch

Immunosuppressive Drugs

STENTYS Sirolimus-Eluting Stent Demonstrates Faster Arterial Healing Than …
MarketWatch
The APPOSITION IV trial enrolled 152 patients suffering from ST-elevation Myocardial Infarction (STEMI) in a double-randomized trial to compare the STENTYS Sirolimus-eluting stent to Medtronic’s Resolute(R) zotarolimus-eluting stent at two different …

and more »
29Oct/13

STENTYS Sirolimus-Eluting Stent Demonstrates Faster Arterial Healing Than … – 4-traders (press release)

Immunosuppressive Drugs

STENTYS Sirolimus-Eluting Stent Demonstrates Faster Arterial Healing Than …
4-traders (press release)
STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today results from the 4-month arm of the APPOSITION IV …

and more »
29Oct/13

STENTYS Sirolimus-Eluting Stent Demonstrates Faster Arterial Healing Than … – Business Wire (press release)

Immunosuppressive Drugs

STENTYS Sirolimus-Eluting Stent Demonstrates Faster Arterial Healing Than …
Business Wire (press release)
PRINCETON, N.J. & PARIS–(BUSINESS WIRE)–STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today …